DK1007055T3 - Anvendelse af amifostin - Google Patents

Anvendelse af amifostin

Info

Publication number
DK1007055T3
DK1007055T3 DK98906688T DK98906688T DK1007055T3 DK 1007055 T3 DK1007055 T3 DK 1007055T3 DK 98906688 T DK98906688 T DK 98906688T DK 98906688 T DK98906688 T DK 98906688T DK 1007055 T3 DK1007055 T3 DK 1007055T3
Authority
DK
Denmark
Prior art keywords
compounds
aminoalkyl
amifostine
adverse
patients
Prior art date
Application number
DK98906688T
Other languages
English (en)
Inventor
Martin Stogniew
Philip S Schein
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of DK1007055T3 publication Critical patent/DK1007055T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
DK98906688T 1997-02-12 1998-02-11 Anvendelse af amifostin DK1007055T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/798,840 US6051563A (en) 1997-02-12 1997-02-12 Methods for the administration of amifostine and related compounds
PCT/US1998/003614 WO1998034622A1 (en) 1997-02-12 1998-02-11 Methods for the administration of amifostine

Publications (1)

Publication Number Publication Date
DK1007055T3 true DK1007055T3 (da) 2004-06-07

Family

ID=25174410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98906688T DK1007055T3 (da) 1997-02-12 1998-02-11 Anvendelse af amifostin

Country Status (11)

Country Link
US (3) US6051563A (da)
EP (1) EP1007055B1 (da)
JP (1) JP2001512447A (da)
AT (1) ATE258797T1 (da)
AU (1) AU750591B2 (da)
CA (2) CA2280773C (da)
DE (1) DE69821498T2 (da)
DK (1) DK1007055T3 (da)
ES (1) ES2216271T3 (da)
PT (1) PT1007055E (da)
WO (1) WO1998034622A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
WO1989007942A1 (en) * 1988-02-23 1989-09-08 U.S. Bioscience Method for protection from chemotherapeutic side effects
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
CA2122342A1 (en) * 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
DE69526395D1 (de) * 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds

Also Published As

Publication number Publication date
DE69821498D1 (de) 2004-03-11
EP1007055B1 (en) 2004-02-04
CA2625727A1 (en) 1998-08-13
EP1007055A1 (en) 2000-06-14
CA2280773A1 (en) 1998-08-13
JP2001512447A (ja) 2001-08-21
US6127351A (en) 2000-10-03
ATE258797T1 (de) 2004-02-15
PT1007055E (pt) 2004-06-30
ES2216271T3 (es) 2004-10-16
DE69821498T2 (de) 2004-12-02
US6051563A (en) 2000-04-18
WO1998034622A1 (en) 1998-08-13
EP1007055A4 (en) 2002-05-29
CA2280773C (en) 2008-07-22
AU6184998A (en) 1998-08-26
AU750591B2 (en) 2002-07-25
US6218377B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
ATE258797T1 (de) Verwendung von amifostin
DK2329829T3 (da) Anveldelse af uridin i kombination med cholin til behandling af neurologiske lidelser
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
GB2368283A (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
DK2186902T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer&#39;s sygdom
BR0116519B1 (pt) cartucho de hemodiafiltraÇço/hemofiltraÇço de diluiÇço intermediÁria.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE239474T1 (de) Verwendung von levobupivacain
DK1604674T3 (da) Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
IT1318667B1 (it) Medicamento antinfiammatorio.
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
FR2807944B1 (fr) Utilisation de l&#39;anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
BR9809286A (pt) Processos para redução de fibrinogênio